• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响肺鳞状细胞癌患者化疗引起的恶心和呕吐的因素。

Factors affecting chemotherapy-induced nausea and vomiting in patients with lung squamous cell carcinoma.

作者信息

Wang Jia

机构信息

Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University Chengdu 610000, Sichuan, China.

出版信息

Am J Transl Res. 2025 Jul 15;17(7):5129-5140. doi: 10.62347/FZAJ6796. eCollection 2025.

DOI:10.62347/FZAJ6796
PMID:40821046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12351587/
Abstract

OBJECTIVE

To identify factors associated with the severity of chemotherapy-induced nausea and vomiting (CINV) in patients with lung squamous cell carcinoma.

METHODS

A retrospective analysis was conducted on 301 LSCC patients who received chemotherapy between January 2021 and December 2024. CINV severity was assessed using the Index of Nausea, Vomiting, and Retching. Post-chemotherapy assessments included blood measurements, inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and serum albumin levels. Multivariate logistic regression was performed to identify factors associated with CINV severity.

RESULTS

A history of coronary heart disease significantly increased the risk of moderate to severe CINV (P = 0.010). Higher forced expiratory volume in one second (FEV) was associated with a reduced risk of severe CINV (P = 0.053). Higher albumin levels were associated with more severe CINV (P = 0.048). Elevated IL-6 levels were found to have a protective effect against severe CINV (P < 0.001). Higher partial pressure of oxygen (PaO) significantly reduced the risk of severe CINV (P = 0.002), while increased partial pressure of carbon dioxide (PaCO) was associated with greater CINV severity (P = 0.017).

CONCLUSION

CINV severity in LSCC patients is influenced by a combination of pulmonary function (FEV, PaO, PaCO), inflammatory markers (IL-6, CRP, TNF-α), serum albumin levels, and cardiovascular comorbidities. These findings provide a foundation for personalized supportive care to enhance the quality of life in patients receiving chemotherapy.

摘要

目的

确定肺鳞状细胞癌患者化疗引起的恶心和呕吐(CINV)严重程度的相关因素。

方法

对2021年1月至2024年12月期间接受化疗的301例肺鳞状细胞癌患者进行回顾性分析。使用恶心、呕吐和干呕指数评估CINV严重程度。化疗后评估包括血液检测、炎症标志物如C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)以及血清白蛋白水平。进行多因素逻辑回归分析以确定与CINV严重程度相关的因素。

结果

冠心病史显著增加了中度至重度CINV的风险(P = 0.010)。较高的一秒用力呼气量(FEV)与严重CINV风险降低相关(P = 0.053)。较高的白蛋白水平与更严重的CINV相关(P = 0.048)。发现IL-6水平升高对严重CINV有保护作用(P < 0.001)。较高的氧分压(PaO)显著降低了严重CINV的风险(P = 0.002),而二氧化碳分压(PaCO)升高与CINV严重程度增加相关(P = 0.017)。

结论

肺鳞状细胞癌患者的CINV严重程度受肺功能(FEV、PaO、PaCO)、炎症标志物(IL-6、CRP、TNF-α)、血清白蛋白水平和心血管合并症的综合影响。这些发现为个性化支持治疗提供了基础,以提高接受化疗患者的生活质量。

相似文献

1
Factors affecting chemotherapy-induced nausea and vomiting in patients with lung squamous cell carcinoma.影响肺鳞状细胞癌患者化疗引起的恶心和呕吐的因素。
Am J Transl Res. 2025 Jul 15;17(7):5129-5140. doi: 10.62347/FZAJ6796. eCollection 2025.
2
A nurse-led multidomain intervention to improve the management of chemotherapy-induced nausea and vomiting in patients with head and neck cancers: A randomized controlled trial.护士主导的多领域干预措施改善头颈部癌症患者化疗所致恶心和呕吐的管理:一项随机对照试验。
Eur J Oncol Nurs. 2024 Jun;70:102615. doi: 10.1016/j.ejon.2024.102615. Epub 2024 May 20.
3
Fact-finding and risk factor analysis of chemotherapy-induced nausea and vomiting in children with solid tumors: a prospective observational study.实体瘤患儿化疗引起恶心和呕吐的现状调查及危险因素分析:一项前瞻性观察研究
BMC Pediatr. 2025 Jan 31;25(1):84. doi: 10.1186/s12887-025-05451-9.
4
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.成人止吐药预防中度或高度致吐性化疗引起的恶心和呕吐:网状荟萃分析。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.
5
The Effectiveness of P6 and Auricular Acupressure as a Complimentary Therapy in Chemotherapy-Induced Nausea and Vomiting Among Patients With Cancer: Systematic Review.P6 点和耳穴按压作为癌症患者化疗引起的恶心和呕吐的补充疗法的效果:系统评价。
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241239110. doi: 10.1177/15347354241239110.
6
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
7
[Interaction of α-amylase and inflammatory response in patients with ventilator-associated pneumonia and their prognostic value].[α-淀粉酶与呼吸机相关性肺炎患者炎症反应的相互作用及其预后价值]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025 Jun;37(6):535-541. doi: 10.3760/cma.j.cn121430-20240409-00321.
8
Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.长延迟(>120 小时)化疗引起的恶心和呕吐(CINV)的患病率和预测因素——系统评价和个体患者数据荟萃分析。
Support Care Cancer. 2023 Aug 3;31(8):505. doi: 10.1007/s00520-023-07978-y.
9
Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.中国四川癌症中心接受中高度致吐性化疗的癌症患者化疗所致恶心呕吐的发生率。
J Cancer Res Clin Oncol. 2021 Sep;147(9):2701-2708. doi: 10.1007/s00432-021-03554-1. Epub 2021 Feb 14.
10
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.

本文引用的文献

1
Cardiovascular health and cancer mortality: evidence from US NHANES and UK Biobank cohort studies.心血管健康与癌症死亡率:来自美国 NHANES 和英国生物银行队列研究的证据。
BMC Med. 2024 Sep 5;22(1):368. doi: 10.1186/s12916-024-03553-2.
2
[Current Status of Self-transcendence among Lung Cancer Patients 
and Its Influencing Factors].[肺癌患者自我超越的现状及其影响因素]
Zhongguo Fei Ai Za Zhi. 2024 Jul 20;27(7):523-528. doi: 10.3779/j.issn.1009-3419.2024.106.16.
3
The Interplay Between Cardiovascular Disease and Lung Cancer.心血管疾病与肺癌之间的相互作用
Cureus. 2024 Jun 23;16(6):e62953. doi: 10.7759/cureus.62953. eCollection 2024 Jun.
4
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.基于代谢肿瘤活性的炎症和营养指数在接受免疫治疗的非小细胞肺癌中的临床影响
Oncol Lett. 2024 Jan 19;27(3):110. doi: 10.3892/ol.2024.14243. eCollection 2024 Mar.
5
Effects of cognitive behavioral therapy on anxiety and depressive symptoms in advanced cancer patients: A meta-analysis.认知行为疗法对晚期癌症患者焦虑和抑郁症状的影响:一项荟萃分析。
Gen Hosp Psychiatry. 2024 Mar-Apr;87:20-32. doi: 10.1016/j.genhosppsych.2024.01.006. Epub 2024 Jan 20.
6
USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity.USP13 通过切换肺 club 细胞谱系可塑性驱动肺鳞状细胞癌。
Mol Cancer. 2023 Dec 13;22(1):204. doi: 10.1186/s12943-023-01892-x.
7
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.肿瘤免疫微环境和NRF2与肺鳞状细胞癌中PD-1阻断联合化疗的临床疗效相关。
Cell Rep Med. 2023 Dec 19;4(12):101302. doi: 10.1016/j.xcrm.2023.101302. Epub 2023 Dec 4.
8
Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.基于肿瘤进展、免疫浸润和干细胞指数鉴定肺鳞状细胞癌的特定预后标志物。
Front Immunol. 2023 Sep 29;14:1236444. doi: 10.3389/fimmu.2023.1236444. eCollection 2023.
9
Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.外周血炎症生物标志物的动态变化反映了新辅助免疫治疗的非小细胞肺癌患者的治疗反应,并预测了预后。
Cancer Sci. 2023 Dec;114(12):4484-4498. doi: 10.1111/cas.15964. Epub 2023 Sep 20.
10
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study.前瞻性队列研究中心血管疾病与肺癌的双向关联。
J Thorac Oncol. 2024 Jan;19(1):80-93. doi: 10.1016/j.jtho.2023.09.004. Epub 2023 Sep 12.